CRDL
Cardiol Therapeutics Inc - Class A (CRDL)
Healthcare • NASDAQ • $1.32+1.54%
- Symbol
- CRDL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $1.32
- Daily Change
- +1.54%
- Market Cap
- $147.42M
- Trailing P/E
- N/A
- Forward P/E
- -7.63
- 52W High
- $1.71
- 52W Low
- $0.88
- Analyst Target
- $7.39
- Dividend Yield
- N/A
- Beta
- 0.42
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Company websiteResearch CRDL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.